# the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

> **NCT07692256** · PHASE2 · RECRUITING · sponsor: **Ain Shams University** · enrollment: 60 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Empagliflozin (EMPA)
- **DRUG:** Standard medical treatment

## Key facts

- **NCT ID:** NCT07692256
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692256, "the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*